Perritt Capital Management Inc Has $529,000 Stake in Pfizer Inc. (NYSE:PFE)

Perritt Capital Management Inc increased its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 19,938 shares of the biopharmaceutical company’s stock after purchasing an additional 522 shares during the quarter. Perritt Capital Management Inc’s holdings in Pfizer were worth $529,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. United Bank boosted its position in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the period. Benjamin Edwards Inc. boosted its holdings in Pfizer by 1,399.9% in the 3rd quarter. Benjamin Edwards Inc. now owns 240,258 shares of the biopharmaceutical company’s stock valued at $6,953,000 after purchasing an additional 224,240 shares during the period. Ascent Group LLC grew its position in shares of Pfizer by 23.3% during the 3rd quarter. Ascent Group LLC now owns 62,712 shares of the biopharmaceutical company’s stock worth $1,815,000 after purchasing an additional 11,867 shares in the last quarter. Hilltop Holdings Inc. increased its holdings in shares of Pfizer by 31.9% during the third quarter. Hilltop Holdings Inc. now owns 102,353 shares of the biopharmaceutical company’s stock worth $2,962,000 after purchasing an additional 24,736 shares during the period. Finally, HighTower Advisors LLC raised its position in shares of Pfizer by 5.2% in the third quarter. HighTower Advisors LLC now owns 3,219,490 shares of the biopharmaceutical company’s stock valued at $93,146,000 after buying an additional 157,775 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 3.2 %

Shares of PFE stock opened at $24.53 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $139.09 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock’s fifty day simple moving average is $26.00 and its 200 day simple moving average is $26.84.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.